TrialScope, a provider of clinical trial solutions and services, has announced its acquisition of substantially all of the assets of Deloitte Analytics, including the PharmaCM business, which provides technology solutions for clinical trial registration and transparency. Terms of the acquisition have not been disclosed, but include an investment in TrialScope by its investors of $5 million for technology development, sales and marketing, in addition to funding the acquisition.

The transaction closed May 30. The PharmaCM business became a part of Deloitte Analytics in 2011 in connection with the acquisition of certain assets of Intrasphere Technologies, a global drug safety and consulting business, by an affiliate of Deloitte Analytics. PharmaCM is a content management platform addressing the registry and lifecycle challenges facing life sciences companies. The platform is the basis for a number of modules that address specific content management and workflow challenges across the clinical study protocol value chain.

Thomas Wicks, general manager of the PharmaCM business and newly appointed chief operating officer of TrialScope, said, "This acquisition was a strategic move for both parties and will benefit all involved—especially our customers. By bringing to market the best tools and technologies to optimize this process, we are not only providing tremendous value in time, cost and resource savings, but compliance and transparency in an increasingly complex and global environment."